You are here

A Single Dose Study to Evaluate the PK-PD Response and Safety of PHA-794428 in Children With Growth Hormone Deficiency

Last updated on March 15, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Brussel, , 1090 Belgium
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Growth Hormone Deficiency
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
6-12 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- 1.Male and female children with a minimum age of 6 years

- 2. Prepubertal as defined by Tanner staging

- 3. Growth hormone deficiency

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- 1. PGHD patients with uncontrolled pituitary tumor growth

- 2. Tumors within 3 mm of the optic chiasm

- 3. Serum ALT and/or AST >= 1.5 times the upper limit of normal range

NCT00314938
Pfizer
Terminated
A Single Dose Study to Evaluate the PK-PD Response and Safety of PHA-794428 in Children With Growth Hormone Deficiency

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Growth Hormone Deficiency
NCT03831880
All Genders
3+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now